Inhibrx Biosciences, Inc.

Inhibrx Biosciences, Inc.

INBX·NASDAQ

$95.22

+1.7%
HealthcareBiotechnology

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.

At a Glance

Live Snapshot
Market Cap$1.40B
EPS-9.0400
P/E Ratio-10.53
Earnings Date08/12/2026

inbx

Operating Cash Flow

Last Annual Value

-129.79M

3-Year CAGR

-4%

5-Year CAGR

-22%

10-Year CAGR

-22%

Inhibrx Biosciences, Inc.

Inhibrx Biosciences, Inc. Competitors Analysis of Operating Cash Flow

INBX · NASDAQ
CompanyOperating Cash Flow
CAGR 3Y
CAGR 5Y
CAGR 10Y
-129.79M
N/AN/AN/A 
-70.30M
N/AN/AN/A
-235.46M
N/AN/AN/A
-102.67M
N/AN/AN/A
-123.34M
N/AN/AN/A
-113.37M
N/AN/AN/A
-143.83M
N/AN/AN/A
-322.98M
N/AN/AN/A
-208.51M
N/AN/AN/A
Inhibrx Biosciences, Inc.

Inhibrx Biosciences, Inc. Fair Value Envelope

INBX · NASDAQ

Our analysis suggests that INBX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $95.22, this represents a potential HIDDEN relative to our calculated worth for Inhibrx Biosciences, Inc..

Intrinsic Value
Current Price: $95.22